Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

45.64 +2.01 (+4.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology ↗

May 28, 2025

VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth...

Via Chartmill

Veracyte to Participate in Upcoming Investor Conferences

May 20, 2025

From Veracyte, Inc.

Via Business Wire

Breaking Down Veracyte: 7 Analysts Share Their Views ↗

May 08, 2025

Via Benzinga

Veracyte Announces First Quarter 2025 Financial Results

May 07, 2025

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts ↗

February 25, 2025

Via Benzinga

Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. ↗

February 06, 2025

A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing?

Via Chartmill

Demystifying Veracyte: Insights From 7 Analyst Reviews ↗

January 29, 2025

Via Benzinga

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch ↗

May 02, 2025

Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch

Via Chartmill

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms ↗

April 26, 2025

ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.

Via Benzinga

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

April 25, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

April 22, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release

April 21, 2025

From Veracyte, Inc.

Via Business Wire

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗

April 17, 2025

A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Via Investor's Business Daily

Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

April 16, 2025

From Veracyte, Inc.

Via Business Wire

Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability. ↗

April 12, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

March 25, 2025

From Veracyte, Inc.

Via Business Wire

While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable. ↗

March 22, 2025

NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

5 Analysts Assess Veracyte: What You Need To Know ↗

March 20, 2025

Via Benzinga

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

March 19, 2025

From Veracyte, Inc.

Via Business Wire

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗

March 12, 2025

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank. ↗

February 27, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive ↗

February 25, 2025

Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit.

Via Benzinga

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

February 24, 2025

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For February 24, 2025 ↗

February 24, 2025

Via Benzinga

Veracyte to Participate in Upcoming Investor Conferences

February 19, 2025

From Veracyte, Inc.

Via Business Wire

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

February 14, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

February 11, 2025

From Veracyte

Via Business Wire

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

February 05, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

February 04, 2025

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.